Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Coeptis Therapeutics Holdings - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COEP
Nasdaq
2834
https://coeptistx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Coeptis Therapeutics Holdings
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
- Feb 26th, 2024 2:00 pm
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
- Feb 7th, 2024 12:30 pm
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
- Jan 4th, 2024 12:30 pm
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
- Dec 5th, 2023 12:00 pm
Coeptis Therapeutics to Present at the Emerging Growth Conference
- Dec 4th, 2023 12:30 pm
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
- Oct 31st, 2023 1:01 pm
Coeptis Therapeutics Announces $2 Million Private Placement
- Oct 24th, 2023 12:30 pm
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
- Oct 11th, 2023 11:30 am
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies
- Oct 9th, 2023 1:15 pm
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting
- Oct 4th, 2023 11:30 am
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa
- Sep 27th, 2023 11:30 am
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection
- Sep 14th, 2023 11:30 am
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment
- Sep 11th, 2023 11:30 am
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer
- Aug 30th, 2023 5:00 pm
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
- Aug 17th, 2023 11:30 am
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic
- Aug 1st, 2023 12:00 pm
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering
- Jun 16th, 2023 8:00 pm
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering
- Jun 14th, 2023 1:28 pm
Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market
- Jun 9th, 2023 11:00 am
Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer
- May 17th, 2023 12:30 pm
Scroll